Immunogenicity and Safety of Two Different Commercial EV71 Vaccines

Hand, Foot and Mouth Disease Clinical Trial

Official title:

A Opened，Randomized and Controlled Trial to Evaluate the Immunity and Safety of Sequential Vaccination of Two Different Commercial EV71 Inactived Vaccines in Healthy Infants Aged 6-35 Months

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03873740
• Other study ID #: EV71-SD-2018-01
• Status: Completed
• Phase: Phase 4
• Start date: November 6, 2018
• Est. completion date: January 23, 2019

Study information

• Verified date: March 2019
• Source: Sinovac Biotech Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the immunogenicity and safety of sequential vaccination of two EV71 inactived vaccines in healthy infants aged 6-35 months.

Description:

This study is a opened,randomized and controlled phase Ⅳ clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of sequential vaccination of two EV71 inactived vaccines in healthy infants aged 6-35 months. EV71 inactived vaccines(Vero cells）was manufactured by Sinovac Biotech Co., Ltd and EV71 inactived vaccines(Human diploid cells）was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.300 infants aged between 6-35 months will be randomly assigned into experimental group in the ratio 1:1:1:1.The experimental group 1 received two doses EV71 inactived vaccines(Vero cells）on day 0 and 30. The experimental group 2 received two doses EV71 inactived vaccines (Human diploid cells）on day 0 and 30. The experimental group 3 received one dose EV71 inactived vaccines (Vero cells）on day 0 and one dose EV71 inactived vaccines (Human diploid cells）on day 30.The experimental group 4 received one dose EV71 inactived vaccines (Human diploid cells）on day 0 and one dose EV71 inactived vaccines (Vero cells）on day 30. To evaluate the immunogenicity of the vaccine, venous blood will be collected for the EV71 neutralizing antibody detection prior to vaccination and 30 days after the 2nd dose vaccination.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 300
• Est. completion date: January 23, 2019
• Est. primary completion date: January 21, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Months to 35 Months

Eligibility

Inclusion Criteria:

• Healthy volunteer aged 6-35 months;
• Proven legal identity;
• Guardians of the participants should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study.

Exclusion Criteria:

• Prior vaccination with EV71 vaccine;
• History of hand,foot and mouth disease;
• Allergy to gentamicin; history of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria,difficulty in breathing, angioneurotic edema, pain, etc;
• Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc;
• Autoimmune diseases or immunodeficiency/immunosuppression;
• Severe neurological disorders (epilepsy, convulsions or convulsions) or psychosis;
• History of thyroidectomy, absence of spleen, functional absence of spleen, and any circumstances leading to absence of spleen or splenectomy;
• Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders;
• Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) in the past 6 months;
• Receipt of any of the following products:

1. Blood product within 3 months prior to study entry;

2. Any live attenuated vaccine within 14 days prior to study entry;

3. Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;

4. Any other study drugs within 30 days prior to study entry;

• Acute disease or acute stage of chronic disease within 7 days prior to study entry;
• Axillary temperature > 37.0?;
• Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators.

Related Conditions & MeSH terms

• Hand, Foot and Mouth Disease
• Mouth Diseases

Intervention

Biological:
• EV71 inactived vaccine(Vero cells)
The EV71 inactived vaccine(Vero cells) was manufactured by Sinovac Biotech Co., Ltd.
• EV71 inactived vaccine(Human diploid cells)
The EV71 inactived vaccine(Human diploid cells) was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.

Locations

Country	Name	City	State
China	Rushan City Center for Disease Control and Prevention	Rushan	Shandong

Sponsors (2)

Lead Sponsor	Collaborator
Sinovac Biotech Co., Ltd	Shandong Province Centers for Disease Control and Prevention

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The seroconversion rates (SCR) of the EV71 neutralizing antibody calculated based on the cutoff value of 1:8.	Subjects whose pre-immune EV71 antibody level < 1:8 and post-immune antibody level = 1:8, or those whose pre-immune antibody level = 1:8 and the increase of post-immune EV71 antibody level = 4 folds are considered seroconverted	30 days after two doses
Secondary	The incidences of adverse reactions after each does	After each dose, a 30-minute safety observation will be conducted immediately. The body temperature, solicited local and general adverse events (AE) on day 0-7 were reported. Unsolicited adverse events on day 0-30 were also reported. Each AE case will be reviewed by the investigator to determine whether or not it was an adverse reaction (The vaccination-related AE).	0-30 days after each dose
Secondary	The incidence of solicited local and general adverse events after each does	After each dose, a 30-minute safety observation will be conducted immediately. The body temperature, solicited local and general adverse events (AE) on day 0-7 were reported. Each AE case will be reviewed by the investigator to determine whether or not it was an adverse reaction (The vaccination-related AE).	0-7 days after each dose
Secondary	Incidence of serious adverse events (SAEs) during the period of safety monitoring	Serious adverse events (SAEs) will be collected during the period of safety monitoring after each dose.	0-30 days after each dose
Secondary	EV71 neutralizing antibody positive rate of each group after two doses.	Subjects whose post-immune antibody level = 1:8 are considered antibody positive.	30 days after two doses
Secondary	The Geometric mean titer (GMT) of the EV71 neutralizing antibody	The GMT 30 days of each group after two doses.	30 days after two doses
Secondary	The geometric mean fold increase (GMI) of the EV71 neutralizing antibody	The GMI 30 days of each group after two doses.	30 days after two doses